General: Edoxabn is a reversible factor Xa inhibitor with high selectivity. During coagulation, factor Xa forms a prothrombinase complex with factor Va on the surface of platelets . Prothrombinase converts prothrombin to thrombin, which in turn converts soluble fibrinogen to insoluble fibrin, the main component of blood clots. Thus, FXa has become a major target for the development of a new generation of anticoagulants.

Function： Edo xaban can be used to prevent serious blood clots from forming due to some irregular heartbeat (atrial fibrillation). It is also used to treat certain blood clots.  It is an anticoagulant, which works by blocking some coagulation proteins in the blood.

Origin: On January 8, 2015, the US Food and Drug Administration (FDA) approved a brand, an anticoagulant drug from the Daiichi Sankyo Company Limited，TYO: 4568 , to reduce the risk of stroke and dangerous thrombosis (systemic embolism) in patients with atrial fibrillation caused by non-valvular heart disease.